BAJEL:NSE:NSE-BAJEL PROJECTS LTD (INR)

COMMON STOCK | Utilities - Regulated Electric |

Last Closing

USD 301.15

Change

-0.95 (-0.31)%

Market Cap

N/A

Volume

0.56M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-03 )

Largest Industry Peers for Utilities - Regulated Electric

Symbol Name Price(Change) Market Cap
NTPC:NSE NTPC Limited

+6.85 (+1.84%)

USD 3,491.30B
POWERGRID:NSE Power Grid Corporation of Indi..

+4.40 (+1.31%)

USD 3,032.00B
NLCINDIA:NSE NLC India Limited

-1.13 (-0.43%)

USD 325.33B
CESC:NSE CESC Limited

+8.98 (+5.65%)

USD 222.72B
GIPCL:NSE Gujarat Industries Power Compa..

+10.95 (+4.52%)

USD 38.84B
DPSCLTD:NSE DPSC Limited

+0.35 (+2.00%)

USD 17.34B
ENERGYDEV:NSE Energy Development Company Lim..

+0.31 (+1.34%)

USD 1.09B

ETFs Containing BAJEL:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Utilities - Regulated Electric) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 128.49% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.49% 100% F 98% N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike